Quadrant Capital Group LLC Alnylam Pharmaceuticals, Inc. Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 251 shares of ALNY stock, worth $64,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares

251

Previous 230 9.13%

Holding current value

$64,735

Previous $55,000 25.45%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$233.81 - $287.01 $4,910 - $6,027	21 Added 9.13%	251 $69,000
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $143 - $247	-1 Reduced 0.43%	230 $55,000
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $10,988 - $14,865	-75 Reduced 24.51%	231 $34,000
Q4 2023 Feb 08, 2024	BUY	$151.41 - $196.57 $4,693 - $6,093	31 Added 11.27%	306 $58,000
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $3,927 - $4,867	23 Added 9.13%	275 $48,000
Q2 2023 Aug 09, 2023	SELL	$185.01 - $212.05 $13,505 - $15,479	-73 Reduced 22.46%	252 $47,000
Q1 2023 May 11, 2023	BUY	$182.66 - $235.53 $3,470 - $4,475	19 Added 6.21%	325 $65,000
Q4 2022 Feb 10, 2023	SELL	$185.53 - $241.31 $927 - $1,206	-5 Reduced 1.61%	306 $72,000
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $1,523 - $2,552	11 Added 3.67%	311 $62,000
Q2 2022 Aug 09, 2022	BUY	$120.42 - $169.29 $842 - $1,185	7 Added 2.39%	300 $44,000
Q1 2022 May 06, 2022	SELL	$127.18 - $173.91 $7,503 - $10,260	-59 Reduced 16.76%	293 $47,000
Q4 2021 Feb 01, 2022	SELL	$159.56 - $209.29 $8,297 - $10,883	-52 Reduced 12.87%	352 $60,000
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $6,620 - $8,101	39 Added 10.68%	404 $76,000
Q2 2021 Aug 09, 2021	BUY	$128.63 - $176.89 $4,759 - $6,544	37 Added 11.28%	365 $62,000
Q1 2021 May 12, 2021	BUY	$126.83 - $175.69 $9,131 - $12,649	72 Added 28.13%	328 $46,000
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $20,535 - $24,549	-167 Reduced 39.48%	256 $33,000
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $28,722 - $39,221	237 Added 127.42%	423 $62,000
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $65,652 - $98,557	-630 Reduced 77.21%	186 $28,000
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $1,396 - $2,009	15 Added 1.87%	816 $89,000
Q4 2019 Feb 03, 2020	BUY	$74.51 - $124.23 $6,035 - $10,062	81 Added 11.25%	801 $90,000
Q3 2019 Oct 24, 2019	BUY	$70.9 - $87.82 $20,419 - $25,292	288 Added 66.67%	720 $56,000
Q2 2019 Jul 24, 2019	SELL	$65.86 - $92.79 $5,861 - $8,258	-89 Reduced 17.08%	432 $30,000
Q1 2019 Apr 29, 2019	BUY	$72.76 - $93.45 $32,014 - $41,118	440 Added 543.21%	521 $46,000
Q4 2018 Jan 17, 2019	SELL	$62.67 - $88.33 $752 - $1,059	-12 Reduced 12.9%	81 $5,000
Q3 2018 Oct 29, 2018	BUY	$87.52 - $122.67 $1,050 - $1,472	12 Added 14.81%	93 $8,000
Q2 2018 Aug 09, 2018	SELL	$88.31 - $107.8 $3,973 - $4,851	-45 Reduced 35.71%	81 $7,000
Q1 2018 May 10, 2018	BUY	$115.92 - $148.54 $5,216 - $6,684	45 Added 55.56%	126 $14,000
Q2 2017 Aug 15, 2017	BUY	N/A	81	81 $6,000

Others Institutions Holding ALNY

# of Institutions

639

Shares Held

108M

Call Options Held

1.15M

Put Options Held

1.07M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Alnylam Pharmaceuticals, Inc. Transaction History